Clinical Pharmacokinetics of Cyclophosphamide

[1]  H. Mouridsen,et al.  Studies on the correlation between rate of biotransformation and haematological toxicity of cyclophosphamide. , 2009, Acta pharmacologica et toxicologica.

[2]  H. Mouridsen,et al.  Pharmacokinetics of cyclophosphamide in renal failure. , 2009, Acta pharmacologica et toxicologica.

[3]  H. Mouridsen,et al.  The biotransformation of cyclophosphamide in man: analysis of the variation in normal subjects. , 2009, Acta pharmacologica et toxicologica.

[4]  F. Juma,et al.  Pharmacokinetics of cyclophosphamide and alkylating activity in man after intravenous and oral administration. , 1979, British journal of clinical pharmacology.

[5]  J. Marini,et al.  Comparative effects of cyclophosphamide, isophosphamide, 4-methylcyclophosphamide, and phosphoramide mustard on murine hematopoietic and immunocompetent cells. , 1979, Journal of the National Cancer Institute.

[6]  T. Mcelwain,et al.  Cyclophosphamide pretreatment reduces the toxic effect of high dose melphalan on intestinal epithelium in sheep. , 1978, European journal of cancer.

[7]  B. Caddy,et al.  A procedure for monitoring cyclophosphamide and isophosphamide in biological samples. , 1978, British journal of clinical pharmacology.

[8]  P. Bovet,et al.  Effect of phenobarbital on plasma levels of cyclophosphamide and its metabolites in the mouse. , 1978, British Journal of Cancer.

[9]  A. R. Torkelson,et al.  Tissue culture cytotoxicity assay for cyclophosphamide metabolites in rat body fluids. , 1978, Journal of pharmaceutical sciences.

[10]  M. Bending,et al.  Haemodialysis during cyclophosphamide treatment. , 1978, British medical journal.

[11]  M. Jarman,et al.  Haemodialysis during cyclophosphamide treatment. , 1978, British medical journal.

[12]  M. D’Incalci,et al.  Simple and sensitive method for the determination of cyclophosphamide by means of a nitrogen--phosphorus-selective detector. , 1978, Journal of chromatography.

[13]  C. Fenselau,et al.  Quantitation by gas chromatography-chemical ionization mass spectrometry of cyclophosphamide, phosphoramide mustard, and nornitrogen mustard in the plasma and urine of patients receiving cyclophosphamide therapy. , 1978, Cancer research.

[14]  O. M. Friedman,et al.  Identification of aldophosphamide as a metabolite of cyclophosphamide in vitro and in vivo in humans. , 1977, Cancer research.

[15]  T. Wagner,et al.  Characterization and quantitative estimation of activated cyclophosphamide in blood and urine. , 1977, Cancer research.

[16]  S. Garattini,et al.  Effect of Phenobarbital on Cyclophosphamide Cytotoxic Activity and Pharmacokinetics in Mice 1 , 1977, Tumori.

[17]  T. Wetters,et al.  The effect of phenobarbital on cyclophosphamide antitumor activity. , 1976, Cancer research.

[18]  D. Alberts,et al.  The effect of allopurinol on cyclophosphamide antitumor activity. , 1976, Cancer research.

[19]  T. Wagner,et al.  Identification and pharmacokinetics of cyclophosphamide (NSC-26271) metabolites in vivo. , 1976, Cancer treatment reports.

[20]  N. Brock.  Comparative pharmacologic study in vitro and in vivo with cyclophosphamide (NSC-26271), cyclophosphamide metabolites, and plain nitrogen mustard compounds. , 1976, Cancer treatment reports.

[21]  C. Fenselau,et al.  Alkylating properties of phosphoramide mustard. , 1976, Cancer research.

[22]  H. Mouridsen,et al.  The metabolism of cyclophosphamide. Dose dependency and the effect of long‐term treatment with cyclophosphamide , 1976, Cancer.

[23]  R. Slavin,et al.  Pathology of high dose intermittent cyclophosphamide therapy. , 1975, Human pathology.

[24]  M. Colvin,et al.  Intensive cyclophosphamide (NSC-26271) therapy for solid tumors. , 1975, Cancer chemotherapy reports.

[25]  M. Witt,et al.  Isolation and mass spectral identification of blood metabolites of cyclophosphamide: evidence for phosphoramide mustard as the biologically active metabolite. , 1975, Biomedical mass spectrometry.

[26]  V. Feil,et al.  Alopecia activity of cyclophosphamide metabolites and related compounds in sheep. , 1974, Cancer research.

[27]  A. Frigerio,et al.  Quantitative GLC determination of cyclophosphamide and isophosphamide in biological specimens. , 1974, Journal of pharmaceutical sciences.

[28]  P. Creaven,et al.  Clinical pharmacology of isophosphamide , 1974, Clinical pharmacology and therapeutics.

[29]  N. Sládek.  Bioassay and relative cytotoxic potency of cyclophosphamide metabolites generated in vitro and in vivo. , 1973, Cancer research.

[30]  R. DeFronzo,et al.  Water intoxication in man after cyclophosphamide therapy. Time course and relation to drug activation. , 1973, Annals of internal medicine.

[31]  C. Fenselau,et al.  A biologically active metabolite of cyclophosphamide. , 1973, Cancer research.

[32]  R. Short,et al.  Effect of phenobarbital and SKF 525A on the toxicity, elimination and metabolism of cyclophosphamide in newborn mice. , 1973, The Journal of pharmacology and experimental therapeutics.

[33]  V. Devita,et al.  Clinical pharmacology of cyclophosphamide. , 1973, Cancer research.

[34]  A. Takamizawa,et al.  Cyclophosphamide metabolites and their related compounds. II. Preparation of an active species of cyclophosphamide and some related compounds , 1973 .

[35]  W. Jusko,et al.  Phenobarbital effects on cyclophosphamide pharmacokinetics in man. , 1972, Cancer research.

[36]  Creaven Pj,et al.  In vitro activation of isophosphamide (NSC-109724), a new oxazaphosphorine, by rat liver microsomes. , 1972 .

[37]  N. Sládek.  Therapeutic efficacy of cyclophosphamide as a function of its metabolism. , 1972, Cancer research.

[38]  J. Bakke,et al.  Metabolism of cyclophosphamide by sheep. , 1972, Journal of agricultural and food chemistry.

[39]  J. Venditti,et al.  The effect of phenobarbital or 2-diethylaminoethyl-2,2-diphenylvalerate on the activation of cyclophosphamide in vivo. , 1972, The Journal of pharmacology and experimental therapeutics.

[40]  P. Neiman,et al.  High‐dose cyclophosphamide therapy for malignant disease. Toxicity, tumor response, and the effects of stored autologous marrow , 1972 .

[41]  J. Cohen,et al.  Pharmacokinetics of cyclophosphamide in man , 1971, British journal of pharmacology.

[42]  S. E. el Dareer,et al.  Urinary metabolites of the antitumor agent cyclophosphamide. , 1971, Molecular pharmacology.

[43]  N. Brock,et al.  Activation of cyclophosphamide in man and animals , 1971, Cancer.

[44]  N. Sládek.  Metabolism of cyclophosphamide by rat hepatic microsomes. , 1971, Cancer research.

[45]  J L Cohen,et al.  Enzymatic basis of cyclophosphamide activation by hepatic microsomes of the rat. , 1970, The Journal of pharmacology and experimental therapeutics.

[46]  G. Robertson,et al.  Effect of cyclophosphamide on advanced lung cancer and the hematological toxicity of large, intermittent intravenous doses. , 1968, Canadian Medical Association journal.

[47]  N. Brock,et al.  [ON THE ACTIVATION OF CYCLOPHOSPHAMIDE IN VIVO AND IN VITRO]. , 1963, Arzneimittel-Forschung.

[48]  O. M. Friedman,et al.  Colorimetric Estimation of Nitrogen Mustards in Aqueous Media. Hydrolytic Behavior of Bis-(β-chloroethyl)amine, nor HN2 , 1961 .

[49]  M. D’Incalci,et al.  Decreased half life of cyclophosphamide in patients under continual treatment. , 1979, European journal of cancer.

[50]  D. L. Hill.  A review of cyclophosphamide , 1975 .

[51]  L. Kvols,et al.  The influence of renal insufficiency on cyclophosphamide induced hematopoietic depression and recovery , 1974 .

[52]  T. A. Connors,et al.  Some studies of the active intermediates formed in the microsomal metabolism of cyclophosphamide and isophosphamide. , 1974, Biochemical pharmacology.

[53]  Adamson Rh,et al.  Metabolism of cyclophosphamide-C14 by various marine species. , 1969 .